Methods for predicting prostate cancer relapse
The present invention relates to methods for determining whether a subject having prostate cancer is at an increased risk for relapse or rapid relapse. It is based, at least in part, on the results of a comprehensive genome analysis of 273 prostate cancer samples, which indicate that the percentage of large size CNVs predicts prostate cancer relapse. In certain embodiments, a method for determining whether a prostate cancer patient has an increased risk of suffering a relapse or a rapid relapse comprises determining the number and size of CNVs in a sample and determining a large size ratio, where if the large size ratio exceeds a particular threshold, the patient is deemed to be at an increased risk for relapse or rapid relapse.
1. A method for treating a prostate cancer patient in need thereof comprising:
a) obtaining a blood sample from the patient;
b) determining the number and size of copy number variations (CNVs) in the sample from the patient;
c) determining a large size ratio, wherein the large size ratio is calculated by dividing the number of CNVs that are larger in size than about 30 kb by the total number of CNVs;
d) determining that the patient is at an increased risk for relapse when the large size ratio is equal to or greater than about 0.28; and
e) performing a prophylactic and/or treatment regimen for the prostate cancer based on the determined increased risk for relapse, wherein the prophylactic and/or treatment regimen is selected from the group consisting of cryotherapy, radiation therapy, chemotherapy, hormone therapy, biologic therapy, bisphosphonate therapy, radical prostatectomy and combinations thereof.
2. A method for treating a prostate cancer patient in need thereof comprising
a) obtaining a blood sample from the patient;
b) determining the number and size of copy number variations (CNVs) in the sample from the patient;
c) determining a large size ratio, wherein the large size ratio is calculated by dividing the number of CNVs that are larger in size than about 30 kb by the total number of CNVs;
d) determining that the patient is at decreased risk for relapse when the large size ratio is less than about 0.28; and
e) performing a biopsy related to the prostate cancer based on the determined decreased risk for relapse.
3. The method of claim 1 , further comprising determining one or more of a Gleason grade of the cancer, nomogram and/or fusion gene MAN2A1-FER status.
4. The method of claim 2 , further comprising determining one or more of a Gleason grade of the cancer, nomogram and/or fusion gene MAN2A1-FER status.
5. A method for treating a prostate cancer patient in need thereof comprising:
a) obtaining a blood sample from the patient;
b) determining the number and size of copy number variations (CNVs) in the sample from the patient;
c) determining a large size ratio, wherein the large size ratio is calculated by dividing the number of CNVs that are larger in size than about 500 kb by the total number of CNVs;
d) determining that the patient is at an increased risk for rapid relapse when the large size ratio is equal to or greater than about 0.02; and
e) performing a prophylactic and/or treatment regimen for the prostate cancer based on the determined increased risk for rapid relapse, wherein the prophylactic and/or treatment regimen is selected from the group consisting of cryotherapy, radiation therapy, chemotherapy, hormone therapy, biologic therapy, bisphosphonate therapy, radical prostatectomy and combinations thereof.
6. The method of claim 5 , further comprising determining one or more of a Gleason grade of the cancer, nomogram and/or fusion gene MAN2A1-FER status.
7. A method for treating a prostate cancer patient in need thereof comprising
a) obtaining a blood sample from the patient;
b) determining the number and size of copy number variations (CNVs) in the sample from the patient;
c) determining a large size ratio, wherein the large size ratio is calculated by dividing the number of CNVs that are larger in size than about 500 kb by the total number of CNVs;
d) determining that the patient is at decreased risk for rapid relapse when the large size ratio is less than about 0.02; and
e) performing a biopsy related to the prostate cancer based on the determined decreased risk for rapid relapse.
8. The method of claim 7 , further comprising determining one or more of a Gleason grade of the cancer, nomogram and/or fusion gene MAN2A1-FER status.